Pharma major Lupin said it has agreed to sell its Japanese injectables business to a wholly owned subsidiary of Neopharma group, the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi.
Lupin has agreed to sell all the issued and outstanding share capital in its unit Kyowa Criticare Co. Ltd to neo ALA Co. Ltd, a unit of Neopharma.
The injectables plant and associated facilities are based out of Atsugi, Japan and has been engaged in sales and contract manufacturing of injectable product.
The transaction does not involve or affect the other operations of Lupin’s Japanese subsidiary Kyowa, namely research, manufacturing, marketing and distribution of oral solids and other dosage forms in Japan.
Lupin said it wants to focus on its drugs business in Japan.
“The divestiture of our injectables business in Japan is a step towards streamlining our Japan operations and bringing sharper focus on building a hybrid (brand/ generics) pharma model in Japan,” said Fabrice Egros, President Lupin APAC and Representative Director— Kyowa .
Suresh Nandiraju, Chief Operating Officer of Neopharma, said the acquisition is synergetic to his firm and will strengthen its product offerings in the Japanese market.
Lupin is one of the world’s top generics manufacturers and is also present in branded formulations, biotechnology products and ingredient manufacturing.
The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues and the 3rd largest pharmaceutical player in the US by prescriptions.
